Al-Natour Sahar H
Department of Dermatology, King Fahd Hospital of the University, Al-Khobar, Saudi Arabia.
J Family Community Med. 2009 May;16(2):41-7.
Cutaneous leishmaniasis (CL) is still a major health problem in many countries including Saudi Arabia. Patients with CL are seen, not only by dermatologists, but also by pediatricians and community physicians. Knowledge of available treatment options is essential.
A literature review utilizing PubMed and Cochrane evidence-based library was undertaken in the last five years.
Several medications and therapeutic modalities are currently in use, though the gold standard remains systemic antimonials. Drug resistance and serious side effects preclude the use of available medications. Newer therapies like liposomal amphotericin B, miltefosine and pentamidine are being used; while it is hoped that other drugs like imiquimod, tamoxifen, PDT and pentamidine structural analogs being tested would offer better efficacy, easier administration and lower toxicity.
After decades of little advance in the treatment of leishmaniasis, there are now several options with newer compounds and combinations of these.
皮肤利什曼病（CL）在包括沙特阿拉伯在内的许多国家仍然是一个主要的健康问题。患有CL的患者不仅会就诊于皮肤科医生，还会有儿科医生和社区医生参与诊治。了解可用的治疗方案至关重要。
在过去五年中利用PubMed和Cochrane循证图书馆进行了文献综述。
目前正在使用几种药物和治疗方式，尽管金标准仍然是全身使用锑剂。耐药性和严重的副作用使得现有药物的使用受到限制。正在使用脂质体两性霉素B、米替福新和喷他脒等新疗法；人们希望正在测试的其他药物如咪喹莫特、他莫昔芬、光动力疗法（PDT）和喷他脒结构类似物能提供更好的疗效、更简便的给药方式和更低的毒性。
在利什曼病治疗几十年进展甚微之后，现在有了几种使用新化合物及其组合的选择。
